Harvard Bioscience Inc. (Nasdaq:HBIO) announced on December 02, 2010 that they have signed a license agreement that grants Harvard Apparatus the worldwide exclusive right to manufacture and sell, for research use, the full line of electroporation-based instruments acquired by Cellectis from CytoPulse in September of 2010.
Cellectis retains all rights to the use of these products for its own research and development programs as well as in clinical trials and prophylactic or therapeutic procedures, for both humans and animals.In the agreement, Cellectis will receive a payment of $1.3M from Harvard Apparatus.
Cellectis will retain some annual licensing fees owed by existing and new customers. The CytoPulse instruments involved include DermaVax, OncoVet, Hybrimune, Cyto-LVT-S and Cyto-LVT-P.
Harvard Bioscience, Inc. develops, manufactures, and markets apparatus and scientific instruments used in life science research in pharmaceutical and biotechnology companies, universities, and government laboratories in the United States and internationally. The companys products target ADMET testing, and molecular biology and liquid handling application areas.
MusclePharm Products Set to Rollout in Vitamin World Locations in 2011
- MusclePharm Strengthens U.S. Distribution Adding Vitamin World to a Network That Includes GNC,
Vitamin Shoppe, Amazon.com, Vitacost.com, Bodybuilding.com and Many More
MusclePharm(NYSE:R) Corporation (OTC:MSLP), one of the fastest growing nutritional supplement companies in the United States, announced on Tuesday that its award-winning products will launch in up to 400 of the Vitamin World retail locations nationwide starting in January 2011.
The agreement starts in January and Vitamin World will introduce MusclePharm's top-selling supplements, including Assault, a popular pre-workout performance-enhancing product, and Shred Matrix, a revolutionary cutting-edge fat loss system, in its retail locations throughout the country.
Vitamin World is widely recognized as one of the top supplement retail providers in the United States and the partnership will allow MusclePharm an opportunity for continued growth.
"We are very excited about adding more retail locations to our nationwide distribution. We know Vitamin World will be a great partner and will further spread the MusclePharm brand nationwide," MusclePharm President Cory Gregory said.
"This new partnership with Vitamin World is a direct reflection of our fulfillment agreement and Distribution Center we recently launched with our manufacturer, which will allow us continue to grow at an impressive rate."
MusclePharm announced the iVitals fulfillment agreement last month and it is one that will greatly reduce backorders and improve turnaround time on all orders, allowing the company to increase its availability nationwide.
MusclePharm products are currently available nationwide in more than 1,200 General Nutrition Centers (NYSE:GNC), 450 Vitamin Shoppes and more than 100 online stores.
MusclePharm has also recently expanded their market to include therapeutic medical modalities beginning with the utilization of Recon, a multi-component therapeutic nutritional supplement in the treatment of people living with HIV and AIDS.
Headquartered in Denver, Colorado, MusclePharm is a rapidly expanding healthy life-style company that develops and manufactures a full line of NSF and scientifically approved nutritional supplements that are 100% free of any banned substances. Based on years of research, MusclePharm products are created through an advanced six-stage research protocol involving the expertise of top nutritional scientists and field tested by more than 100 elite professional athletes from various sports including the NFL, MMA, and MLB.
The Company's propriety and award winning products address all categories of an active lifestyle including muscle building, weight loss, and maintaining general fitness through a daily nutritional supplement regimen.
MusclePharm is sold in over 120 countries and available in over 5,000 U.S. retail outlets that include GNC, and Vitamin Shoppe, as well as over 100 online stores, including bodybuilding.com, Amazon and Vitacost.com.
PLX Technology Inc. (Nasdaq:PLXT) announced on December 07, 2010, immediate availability of a new reference design kit capable of breathing new life connectivity into older PCI-based PCs by providing a bridge to high-performance SuperSpeed USB peripheral devices. “Our lab tests confirm excellent performance results of 139 Mbytes/s when reading data from a USB 3.0 SSD,” said Jimmy Chou, PLX marketing director for USB products.
“This is faster than IEEE 1394B and eSATA drives. Additionally, this performance meets or exceeds that of most PCI Express-to-USB 3.0 host boards in the same test environment”
PLX Technology, Inc. designs, develops, manufactures, and sells integrated circuits. The companys products include PCI Express switches for fan-out in servers and storage systems, dual graphics in gaming and workstation systems, control planes in networking and communications systems, and backplanes in embedded and industrial equipment.
Its products also include PCI Express bridges that upgrade conventional PCI products for use in new PCI Express systems.
GreenHouse Holdings, Inc., a leading integrator of some of the world’s most innovative environmental sustainability systems, eco-friendly infrastructure, and public safety strategies and technologies, has retained Rubenstein Public Relations (http://www.rubensteinpr.com) to generate media exposure for GRHU’s efficient and environmentally sustainable innovations.
Based in San Diego, California, GreenHouse Holdings is a sustainable solutions integrator with a variety of services that address needs ranging from alternative/renewable energy and energy conservation to cost effective, rapidly deployable infrastructure and sustainable construction. GreenHouse Holdings provides solutions for single households, corporations, communities, regions, and the federal government that mitigate disposal costs and convert waste streams into valuable resources.
To learn more about GRHU visit: http://www.greenhouseintl.com
Allos Therapeutics, Inc. (Nasdaq:ALTH) announced on December 10, 2010, the presentation of further data from the Company’s randomized, international Phase 2b investigational study of FOLOTYN® (pralatrexate injection) relative to erlotinib in patients with Stage IIIB/IV (advanced) non-small cell lung cancer (NSCLC) at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology.
The presentation, which includes additional results from several pre-specified analyses, reinforces the favorable survival data observed with FOLOTYN in patients with advanced NSCLC—including outcomes observed in patients with non-squamous and squamous histologies, as well as results from an analysis adjusting for important baseline factors and potential imbalances in the number of patients between cohorts.
Allos Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing anti-cancer therapeutics. It is developing FOLOTYN (pralatrexate injection), a folate analogue metabolic inhibitor, for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.
The company is also developing FOLOTYN as a single agent and in combination therapy regimens in various hematologic malignancies and solid tumor indications, including stage IV breast cancer and recurrent/metastatic head and neck cancer.
Sign-Up For Free Stock Alerts At http://crwepicks.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.The CRWEPicks.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer ( http://crwepicks.com/disclaimer ) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEPicks.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. ( read more at http://crwepicks.com/disclaimer ) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period.
Crown Equity Holdings Inc. (OTCPK:CRWE) has received five thousand dollars and anticipates receiving another forty five thousand dollars in cash from a third party for 30 (thirty) days of advertising for MusclePharm Corporation (OTCQB:MSLP).
Crown Equity Holdings Inc. (OTCPK:CRWE) has received ten thousand dollars in cash and anticipates another ten thousand dollars in cash from the company for 60 days of advertisement services for Green House Holdings, Inc. (OTCQB:GRHU). In addition to the cash, Crown Equity Holdings Inc. (OTCPK:CRWE) also anticipates receiving 20,000 shares of 144 restricted stocks from a third party.